Developer docs
API playgroundTry for free, no card

Search company profiles

Cipher Pharmaceuticals

Full company profile

uuid0004sdc

Namestring
Cipher Pharmaceuticals
Legal namestring
Cipher Pharmaceuticals Inc.
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Cipher Pharmaceuticals is a publicly traded specialty pharmaceutical company headquartered in Mississauga, Ontario, that acquires and commercializes differentiated prescription products in dermatology and anti-parasitic therapeutics. Its commercial portfolio is anchored by Natroba (spinosad), an FDA-approved topical treatment for head lice and scabies acquired from ParaPRO in July 2024 for US$89.5M, and Epuris, the leading isotretinoin product for severe acne with 45% Canadian market share. The company sells Natroba in the US through a 50-person specialty field sales force targeting dermatologists, family practitioners, infectious disease specialists, and pediatricians, and markets Epuris in Canada through its domestic sales infrastructure.

Cipher generates revenue through direct product sales (Natroba in the US, Epuris in Canada), licensing royalties (Absorica portfolio licensed to Sun Pharmaceuticals in the US, Epuris in Mexico via Galephar/Italmex), and out-licensed products such as Lipofen. The April 2026 launch of a CaryHealth-powered direct-to-patient platform extends Natroba's access model through telehealth consultations and same-day pharmacy delivery. Out-licensed products and pipeline assets (MOB-015 for nail fungus, CF-101 for psoriasis, DTR-001 for tattoo removal) round out the franchise.

The company operates with high gross margins (Natroba at 83%, blended Q4 2025 at 81%), $5M of outstanding debt against $6.4M of cash and an $85M available credit facility as of March 2026, and a market capitalization of approximately C$425.48M. Cipher's strategy centers on a buy-and-commercialize model supplemented by US platform expansion out of Carmel, Indiana, with active business development for additional acquisitions and licensing deals.

Short descriptiontext

Cipher Pharmaceuticals is a TSX-listed specialty pharmaceutical company that acquires and commercializes differentiated dermatology and anti-parasitic prescription products, anchored by Natroba (head lice/scabies) in the US and Epuris (isotretinoin) in Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMississauga, Canada
HQ citystring
Mississauga
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, dermatology treatments, prescription therapeutics, anti-parasitic medications, isotretinoin products
Industry3 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAE
Dermatology & Topical Skin Treatments
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Dermatology Pharmaceuticals
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Revenue
TypeOne Time License
Description

Direct product sales primarily in Canada (Epuris and other dermatology products) and US (Natroba through acquired commercial operations). Revenue from Canadian portfolio was $4.5M in Q1 2026 and Natroba contributed $6.9M in Q1 2026.

biospace.com
2Licensing Revenue
TypeLicensing Royalties
Description

Royalties and licensing fees from partnered products including Absorica portfolio in US (Sun Pharmaceuticals), Epuris in Mexico (Galephar/Italmex), and net sales royalties. Licensing revenue was $1.1M in Q1 2026, up 52% year-over-year.

seekingalpha.com
3Natroba US Operations
TypeOne Time License
Description

Acquired US-based commercial operations including direct sales of Natroba and authorized generic Spinosad through 50-person sales force. Generated $30M in product revenue in 2025 with 83% gross margin.

cipherpharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Natroba
Description

Topical prescription treatment for head lice and scabies; acquired from ParaPRO in July 2024

cipherpharma.com
+3 more records
Core offering1 text field

Cipher Pharmaceuticals is a specialty pharmaceutical company that develops, acquires, and commercializes differentiated prescription products primarily in dermatology and anti-parasitic treatments. Its portfolio includes Natroba (spinosad) for head lice and scabies, Epuris (isotretinoin) for severe acne, out-licensed products such as the Absorica portfolio and Lipofen, and a late-stage pipeline including MOB-015 for onychomycosis, CF-101 for psoriasis, and DTR-001 for tattoo removal. The company markets products through a US field sales force, Canadian sales infrastructure, and international licensing partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Natroba achieved $30M revenue with 83% gross margin in 2025 (first partial year post-acquisition)
+2 more records
Product overview1 text field

Cipher Pharmaceuticals is a specialty pharmaceutical company with a diversified portfolio of commercial and pipeline products, primarily focused on dermatology. The core commercial products include Natroba (spinosad), an FDA-approved prescription treatment for head lice and scabies acquired from ParaPRO in July 2024, and Epuris, the leading isotretinoin acne treatment in Canada. The company also has out-licensed products including the Absorica isotretinoin portfolio and Lipofen. The pipeline includes MOB-015 for nail fungus (Canadian rights held), CF-101 for psoriasis, and DTR-001 for tattoo removal. Cipher markets products directly in Canada and the U.S., and through partners in South America.

Product and service4 records
1Natroba (Spinosad)
CategoryDermatology / Anti-parasitic
Description

A topical prescription treatment for head lice and scabies. It is the only FDA-approved prescription head lice treatment with a 'Complete Cure' designation and demonstrated clinical superiority to Nix in phase III trials. The scabies indication carries FDA exclusivity and patent protection until 2033. Acquired from ParaPRO in July 2024.

2Epuris
CategoryDermatology
Description

An isotretinoin product for the treatment of severe acne. It is the #1 prescribed isotretinoin product by dermatologists in Canada with 45% market share. Launched in Mexico in May 2023 through partnerships with Italmex and Galephar.

3Absorica Portfolio
4Lipofen
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Partnership to launch direct-to-patient platform for Natroba, integrating telehealth consultations, same-day pharmacy delivery, and prescription tracking. Platform replaces fragmented virtual-care workflows with unified digital-first access model.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-29
Description

Cipher acquired global product rights for Natroba (Spinosad) and ParaPRO's US commercial sales team of 50 employees for $89.5 million ($80M cash + $9.5M in Cipher shares). ParaPRO founder continues involvement and became Cipher's second largest shareholder. Cipher gained US headquarters in Carmel, Indiana and platform for future dermatology product launches.

3Moberg Pharma AB
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cipher holds exclusive Canadian rights to MOB-015 (nail fungus treatment). Moberg obtained EU approval for MOB-015 across 13 countries and completed Phase 3 enrollment in North America with topline results expected January 2025. Cipher preparing Health Canada regulatory submission.

cipherpharma.com
4Galephar Pharmaceutical Research
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership for commercial manufacturing and distribution of Epuris in Mexico. Galephar's partner Italmex Pharma handles commercial launch, with Epuris officially launched in Mexico in May 2023.

cipherpharma.com
5Italmex Pharma S.A.
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Commercial partner for Epuris launch in Mexico through partnership with Galephar. Generated $0.1M royalty revenue in Q2 2023 from initial sales.

cipherpharma.com
6Sun Pharmaceuticals
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Extended distribution and supply agreement for Absorica portfolio in US through December 2026 (Absorica, Absorica AG) and December 2024 (Absorica LD). Cipher receives licensing revenue from product shipments and royalties.

cipherpharma.com
7Sun Pharmaceuticals (Arbitration)
Strategic tierMinorTypeOthers
Description

Cipher received favorable arbitration award against Sun Pharmaceuticals regarding dispute over clinical data and contractual obligations. Arbitrator declared Cipher owner of data and awarded damages and future royalties. Sun filed petition seeking to vacate parts of award.

newswire.ca
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cipher holds exclusive Canadian rights to CF-101 (Piclidenoson) for treatment of moderate to severe psoriasis. Partner received positive FDA feedback on registration plan for pivotal Phase III trial and Phase III COMFORT study met primary endpoint of superiority.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Padagis
TypeDirect peer
Description

Specialty pharma focused on dermatology, pain, and women's health, with branded and complex generic products. Comparable specialty pharma peer with similar product acquisition strategy and North American commercial footprint.

TypeEmerging player
Description

US-listed late-stage dermatology company focused on immuno-dermatology (psoriasis, atopic dermatitis, seborrheic dermatitis). Comparable small-cap dermatology specialty peer with similar commercial-stage strategy and physician sales force build-out.

TypeBroad incumbent
Description

Large diversified specialty pharma with a major dermatology franchise (Ortho Dermatologics) covering acne, psoriasis, and actinic keratosis. While much broader than Cipher, it competes in the same dermatology prescription channels and physician relationships.

TypeEmerging player
Description

Emerging dermatology company developing topical therapies for inflammatory skin conditions. Comparable emerging peer in dermatology specialty pharma with pipeline-stage assets targeting similar physician specialties.

TypeDirect peer
Description

Former owner of Natroba (Spinosad), whose commercial team and global product rights Cipher acquired in July 2024 for $89.5M. Direct historical peer in the lice/scabies prescription market and continuing partner relationship.

TypeDirect peer
Description

Australian specialty pharma with dermatology and women's health franchises, including branded and generic dermatology products. Comparable small-cap specialty pharma with similar mix of in-licensed and acquired dermatology assets serving physicians.

TypeDirect peer
Description

Pure-play global dermatology company with leading prescription and aesthetic product portfolios across acne, rosacea, and skin conditions. Highly comparable to Cipher as a focused dermatology specialty pharma serving physicians and consumers worldwide.

TypeDirect peer
Description

Privately-held specialty dermatology company with a portfolio spanning psoriasis, atopic dermatitis, and skin infections. Direct peer in dermatology specialty pharma with comparable physician-targeted commercial models and Nordic HQ similar to Cipher's small-cap scale.

TypeBroad incumbent
Description

Generic-focused specialty pharma with a dermatology generics portfolio serving US and Canadian markets. Comparable as a dermatology-focused pharma operating in both the US and Canada, though at a much larger scale and with a generics rather than branded focus.

10Moberg Pharma AB
TypeDirect peer
Description

Swedish specialty pharma developing MOB-015 (nail fungus) — Cipher's exclusive Canadian licensing partner. Directly comparable as a small dermatology-focused pharma with a single-asset commercialization model in the same nail fungus category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cipher Pharmaceuticals

Specialty Dermatology Pharmaceuticalscipherpharma.com

Cipher Pharmaceuticals is a TSX-listed specialty pharmaceutical company that acquires and commercializes differentiated dermatology and anti-parasitic prescription products, anchored by Natroba (head lice/scabies) in the US and Epuris (isotretinoin) in Canada.

What Cipher Pharmaceuticals does

Cipher Pharmaceuticals is a publicly traded specialty pharmaceutical company headquartered in Mississauga, Ontario, that acquires and commercializes differentiated prescription products in dermatology and anti-parasitic therapeutics. Its commercial portfolio is anchored by Natroba (spinosad), an FDA-approved topical treatment for head lice and scabies acquired from ParaPRO in July 2024 for US$89.5M, and Epuris, the leading isotretinoin product for severe acne with 45% Canadian market share. The company sells Natroba in the US through a 50-person specialty field sales force targeting dermatologists, family practitioners, infectious disease specialists, and pediatricians, and markets Epuris in Canada through its domestic sales infrastructure.

Cipher generates revenue through direct product sales (Natroba in the US, Epuris in Canada), licensing royalties (Absorica portfolio licensed to Sun Pharmaceuticals in the US, Epuris in Mexico via Galephar/Italmex), and out-licensed products such as Lipofen. The April 2026 launch of a CaryHealth-powered direct-to-patient platform extends Natroba's access model through telehealth consultations and same-day pharmacy delivery. Out-licensed products and pipeline assets (MOB-015 for nail fungus, CF-101 for psoriasis, DTR-001 for tattoo removal) round out the franchise.

The company operates with high gross margins (Natroba at 83%, blended Q4 2025 at 81%), $5M of outstanding debt against $6.4M of cash and an $85M available credit facility as of March 2026, and a market capitalization of approximately C$425.48M. Cipher's strategy centers on a buy-and-commercialize model supplemented by US platform expansion out of Carmel, Indiana, with active business development for additional acquisitions and licensing deals.

Cipher Pharmaceuticals firmographics

Firmographics
Name
Cipher Pharmaceuticals
Legal name
Cipher Pharmaceuticals Inc.
Website
https://cipherpharma.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
Cipher Pharmaceuticals is a TSX-listed specialty pharmaceutical company that acquires and commercializes differentiated dermatology and anti-parasitic prescription products, anchored by Natroba (head lice/scabies) in the US and Epuris (isotretinoin) in Canada.
Ownership category
akta.pro rank

Cipher Pharmaceuticals industry classification

Industry
Product category
Specialty Dermatology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAE
Dermatology & Topical Skin Treatments
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Specialty pharmaceuticals
  • Dermatology treatments
  • Prescription therapeutics
  • Anti-parasitic medications
  • Isotretinoin products

Where Cipher Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Mississauga
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Cipher Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations

Revenue model

  1. Product Revenue: Direct product sales primarily in Canada (Epuris and other dermatology products) and US (Natroba through acquired commercial operations). Revenue from Canadian portfolio was $4.5M in Q1 2026 and Natroba contributed $6.9M in Q1 2026.
  2. Licensing Revenue: Royalties and licensing fees from partnered products including Absorica portfolio in US (Sun Pharmaceuticals), Epuris in Mexico (Galephar/Italmex), and net sales royalties. Licensing revenue was $1.1M in Q1 2026, up 52% year-over-year.
  3. Natroba US Operations: Acquired US-based commercial operations including direct sales of Natroba and authorized generic Spinosad through 50-person sales force. Generated $30M in product revenue in 2025 with 83% gross margin.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels3 records

Cipher Pharmaceuticals product offering

Product offering

Core offering

Cipher Pharmaceuticals is a specialty pharmaceutical company that develops, acquires, and commercializes differentiated prescription products primarily in dermatology and anti-parasitic treatments. Its portfolio includes Natroba (spinosad) for head lice and scabies, Epuris (isotretinoin) for severe acne, out-licensed products such as the Absorica portfolio and Lipofen, and a late-stage pipeline including MOB-015 for onychomycosis, CF-101 for psoriasis, and DTR-001 for tattoo removal. The company markets products through a US field sales force, Canadian sales infrastructure, and international licensing partners.

Product overview

Cipher Pharmaceuticals is a specialty pharmaceutical company with a diversified portfolio of commercial and pipeline products, primarily focused on dermatology. The core commercial products include Natroba (spinosad), an FDA-approved prescription treatment for head lice and scabies acquired from ParaPRO in July 2024, and Epuris, the leading isotretinoin acne treatment in Canada. The company also has out-licensed products including the Absorica isotretinoin portfolio and Lipofen. The pipeline includes MOB-015 for nail fungus (Canadian rights held), CF-101 for psoriasis, and DTR-001 for tattoo removal. Cipher markets products directly in Canada and the U.S., and through partners in South America.

Differentiator

Problem solved

Functional benefit

Brands

  • Natroba: Topical prescription treatment for head lice and scabies; acquired from ParaPRO in July 2024
  • Epuris
  • Absorica
  • Lipofen

Products and services

  • Natroba (Spinosad) A topical prescription treatment for head lice and scabies. It is the only FDA-approved prescription head lice treatment with a 'Complete Cure' designation and demonstrated clinical superiority to Nix in phase III trials. The scabies indication carries FDA exclusivity and patent protection until 2033. Acquired from ParaPRO in July 2024.
  • Epuris An isotretinoin product for the treatment of severe acne. It is the #1 prescribed isotretinoin product by dermatologists in Canada with 45% market share. Launched in Mexico in May 2023 through partnerships with Italmex and Galephar.
  • Absorica Portfolio
  • Lipofen

Quantifiable outcome

  • Natroba achieved $30M revenue with 83% gross margin in 2025 (first partial year post-acquisition)
  • +2 more outcomes

Companies that use Cipher Pharmaceuticals

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Cipher Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Cipher Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • CaryHealthcoreStrategic or Co-development Partner · 7 April 2026Partnership to launch direct-to-patient platform for Natroba, integrating telehealth consultations, same-day pharmacy delivery, and prescription tracking. Platform replaces fragmented virtual-care workflows with unified digital-first access model.
  • ParaPRO LLCcoreStrategic or Co-development Partner · 29 July 2024Cipher acquired global product rights for Natroba (Spinosad) and ParaPRO's US commercial sales team of 50 employees for $89.5 million ($80M cash + $9.5M in Cipher shares). ParaPRO founder continues involvement and became Cipher's second largest shareholder. Cipher gained US headquarters in Carmel, Indiana and platform for future dermatology product launches.
  • Moberg Pharma ABcoreStrategic or Co-development PartnerCipher holds exclusive Canadian rights to MOB-015 (nail fungus treatment). Moberg obtained EU approval for MOB-015 across 13 countries and completed Phase 3 enrollment in North America with topline results expected January 2025. Cipher preparing Health Canada regulatory submission.
  • Galephar Pharmaceutical ResearchminorChannel Partner/ Reseller/ DistributorPartnership for commercial manufacturing and distribution of Epuris in Mexico. Galephar's partner Italmex Pharma handles commercial launch, with Epuris officially launched in Mexico in May 2023.
  • Italmex Pharma S.A.minorChannel Partner/ Reseller/ DistributorCommercial partner for Epuris launch in Mexico through partnership with Galephar. Generated $0.1M royalty revenue in Q2 2023 from initial sales.
  • Sun PharmaceuticalscoreChannel Partner/ Reseller/ DistributorExtended distribution and supply agreement for Absorica portfolio in US through December 2026 (Absorica, Absorica AG) and December 2024 (Absorica LD). Cipher receives licensing revenue from product shipments and royalties.
  • Sun Pharmaceuticals (Arbitration)minorOthersCipher received favorable arbitration award against Sun Pharmaceuticals regarding dispute over clinical data and contractual obligations. Arbitrator declared Cipher owner of data and awarded damages and future royalties. Sun filed petition seeking to vacate parts of award.
  • Canfite BiopharmaminorStrategic or Co-development PartnerCipher holds exclusive Canadian rights to CF-101 (Piclidenoson) for treatment of moderate to severe psoriasis. Partner received positive FDA feedback on registration plan for pivotal Phase III trial and Phase III COMFORT study met primary endpoint of superiority.

Scale indicators14 records

Recent moves8 records

Expansion highlights5 records

Cipher Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Padagis: Specialty pharma focused on dermatology, pain, and women's health, with branded and complex generic products. Comparable specialty pharma peer with similar product acquisition strategy and North American commercial footprint.
  • ParaPRO LLC: Former owner of Natroba (Spinosad), whose commercial team and global product rights Cipher acquired in July 2024 for $89.5M. Direct historical peer in the lice/scabies prescription market and continuing partner relationship.
  • Mayne Pharma Group: Australian specialty pharma with dermatology and women's health franchises, including branded and generic dermatology products. Comparable small-cap specialty pharma with similar mix of in-licensed and acquired dermatology assets serving physicians.
  • Galderma: Pure-play global dermatology company with leading prescription and aesthetic product portfolios across acne, rosacea, and skin conditions. Highly comparable to Cipher as a focused dermatology specialty pharma serving physicians and consumers worldwide.
  • Leo Pharma: Privately-held specialty dermatology company with a portfolio spanning psoriasis, atopic dermatitis, and skin infections. Direct peer in dermatology specialty pharma with comparable physician-targeted commercial models and Nordic HQ similar to Cipher's small-cap scale.
  • Moberg Pharma AB: Swedish specialty pharma developing MOB-015 (nail fungus) — Cipher's exclusive Canadian licensing partner. Directly comparable as a small dermatology-focused pharma with a single-asset commercialization model in the same nail fungus category.

Emerging players

  • Arcutis Biotherapeutics: US-listed late-stage dermatology company focused on immuno-dermatology (psoriasis, atopic dermatitis, seborrheic dermatitis). Comparable small-cap dermatology specialty peer with similar commercial-stage strategy and physician sales force build-out.
  • Dermavant Sciences: Emerging dermatology company developing topical therapies for inflammatory skin conditions. Comparable emerging peer in dermatology specialty pharma with pipeline-stage assets targeting similar physician specialties.

Broad incumbents

  • Bausch Health Companies: Large diversified specialty pharma with a major dermatology franchise (Ortho Dermatologics) covering acne, psoriasis, and actinic keratosis. While much broader than Cipher, it competes in the same dermatology prescription channels and physician relationships.
  • Taro Pharmaceutical Industries: Generic-focused specialty pharma with a dermatology generics portfolio serving US and Canadian markets. Comparable as a dermatology-focused pharma operating in both the US and Canada, though at a much larger scale and with a generics rather than branded focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cipher Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cipher Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Cipher Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cipher Pharmaceuticals M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cipher Pharmaceuticals

What does Cipher Pharmaceuticals do?

Cipher Pharmaceuticals is a specialty pharmaceutical company that develops, acquires, and commercializes differentiated prescription products primarily in dermatology and anti-parasitic treatments. Its portfolio includes Natroba (spinosad) for head lice and scabies, Epuris (isotretinoin) for severe acne, out-licensed products such as the Absorica portfolio and Lipofen, and a late-stage pipeline including MOB-015 for onychomycosis, CF-101 for psoriasis, and DTR-001 for tattoo removal. The company markets products through a US field sales force, Canadian sales infrastructure, and international licensing partners.

Is Cipher Pharmaceuticals a public or private company?

Cipher Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Cipher Pharmaceuticals founded?

Cipher Pharmaceuticals was founded in 2000. It employs 51 to 100 people.

Where is Cipher Pharmaceuticals based?

Cipher Pharmaceuticals is headquartered in Mississauga, Canada, in the North America region.

How does Cipher Pharmaceuticals make money?

Three revenue lines are on record. Product Revenue is the primary driver. The others are licensing Revenue and natroba US Operations.

Who are Cipher Pharmaceuticals's main competitors?

Direct peers on record are Padagis, ParaPRO LLC, Mayne Pharma Group, Galderma, Leo Pharma and Moberg Pharma AB. Emerging players are Arcutis Biotherapeutics and Dermavant Sciences. Broad incumbents are Bausch Health Companies and Taro Pharmaceutical Industries.

Does Cipher Pharmaceuticals have an API?

No public API is recorded for Cipher Pharmaceuticals.

What industry is Cipher Pharmaceuticals in?

Cipher Pharmaceuticals's product category is Specialty Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StResults: Cipher Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesCipher Pharmaceuticals reported a statutory EPS of US$0.42, 101% above consensus, while revenue of US$13m met expectations. Analysts cut their 2027 revenue forecast to US$52.7m and EPS to US$0.84, lowering the price target to CA$18.38. Revenue growth is expected to slow to 5.2% annually, below the industry's 9.6%.YahooCipher Pharmaceuticals Inc (CPHRF) (Q3 2026) Earnings Call Highlights: Strong Margins and ...Cipher Pharmaceuticals reported Q3 2026 net revenue of $12.7 million, down 1% year-over-year, with gross margin at 82% and adjusted EBITDA margin at 57%. The company won a $5.7 million arbitration award and a 15% royalty on Zorica LD sales through 2040. It remains debt-free with a cash balance of $15.3 million at quarter-end.MarketBeatWhat Cipher Pharmaceuticals (CPH) Said on Its Q3 Earnings CallCipher Pharmaceuticals reported Q3 revenue of $12.7 million, down 1% year over year, while net income rose to $10.9 million, up from $5.5 million. The increase was driven by an arbitration award of $5.7 million and higher Canadian Epuris sales, offsetting lower U.S. Natroba sales. The company remains debt-free with $20 million in cash and is pursuing acquisitions.Investing.comEarnings call transcript: Cipher Pharmaceuticals tops Q3 2026 EPS forecastCipher Pharmaceuticals reported Q3 2026 adjusted EPS of $0.42, beating the $0.2138 consensus, while revenue of $12.7M missed the $13.13M forecast by 3.3%. The earnings beat was driven by an arbitration award, with Natroba sales down 12% and Epuris market share rising to 48.7% in Canada.TradingViewCipher Pharmaceuticals Q3 2026 Earnings Call Is LiveCipher Pharmaceuticals' Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending could move markets.NasdaqCIPHER PHARMACEUTICALS INC Announces Advance In Q3 ProfitCipher Pharmaceuticals reported a third-quarter profit of $10.89 million, up from $5.50 million a year earlier, with EPS of $0.42 versus $0.21. Revenue fell 1.0% to $12.70 million from $12.83 million.NewswireCipher Pharmaceuticals Reports Third Quarter 2026 ResultsCipher Pharmaceuticals reported Q3 2026 net revenue of $12.7 million, down 1% year-over-year, with net income of $10.9 million, up 98% due to Arbitration Award income. Adjusted EBITDA fell 1% to $7.2 million, and the company held $15.3 million in cash with no debt.Simply Wall StThese Canadian Biotech Stocks Are Top Of The Class For November 2026Three Canadian biotech stocks—Auxly Cannabis Group, Cipher Pharmaceuticals, and Green Thumb Industries—are highlighted for November 2026, citing their balance sheets and valuations. Auxly reports CA$166M venture capital revenue, Cipher has a CA$50M specialty portfolio, and Green Thumb holds a net cash position with buybacks. The article notes regulatory and cost shifts could affect margins.NewswireCipher Pharmaceuticals Schedules Q3 2026 Earnings Release and Conference CallCipher Pharmaceuticals announced it will release its Q3 2026 financial results after market close on November 12, 2026, and hold a conference call on November 13 at 8:30 a.m. ET. The company will also provide dial-in and webcast details for the call.MarketBeatCipher Pharmaceuticals (TSE:CPH) Stock Price Crosses Below Fifty Day Moving Average - Time to Sell?Cipher Pharmaceuticals shares fell below their 50-day moving average on Friday, trading at C$13.39. The company reported Q2 EPS of C$0.21 with revenue of C$17.14 million, and director Craig Mull bought 20,000 shares at C$14.16 each.